Artificial Intelligence/Machine Learning

How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.

Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.

Peter Ronco, CEO, Emmes, explains how the company is investing in transparent goal setting, comprehensive education, and evolving talent strategies to embed AI-driven workflows across all teams—transforming the culture to embrace technology as a catalyst for innovation and efficiency in clinical development.

Brian Ongioni, chief product officer, uMotif, shares how early collaboration with patients and clinical sites helps shape intuitive, accessible digital health tools—and why co-design is key to building effective clinical research platforms.

Peter Ronco, CEO, Emmes, explains why AI in clinical development still needs human oversight despite widespread hype.

Peter Ronco, CEO, Emmes, explains how public sector leaders are driving innovation in clinical development through automation, long-term data utilization, and experimental trial design—despite the private sector dominating the conversation around artificial intelligence.

Using a recent survey on the adoption of AI/ML conducted by the Tufts CSDD as context, pharma leaders discussed how they are using these technologies to optimize trial execution.

Balancing the emerging benefits of AI in pharmacovigilance with new responsibilities and demands from regulators in enhancing efficiency and safety.

In this Q&A, Megan Bailey, EVP and president of central laboratories and international, Labcorp, discusses how central labs are evolving beyond testing to become strategic partners in clinical trial success.

In this video interview, Jim Kremidas, executive director, Association for MultiSite Research Corporations (AMRC), highlights opportunities to improve upon inefficiencies that currently exist in clinical workflows.

A blend of FSO and FSP models in the landscape of artificial intelligence can ensure CROs stay up to date with the unique demands of industry.

In this video interview, Michel van Harten, MD, CEO, myTomorrows, highlights the potential of artificial intelligence in digital twin technology.

How digital intake solutions driven by technological advancements can help overcome the challenges of operating across different regulatory markets.

In this video interview, Michel van Harten, MD, CEO, myTomorrows, discusses how patient education and remote monitoring can help with reducing the burden of trial participation.

In this video interview, Michel van Harten, MD, CEO, myTomorrows, highlights how artificial intelligence can be used to address logistical barriers such as access and treatment cost.

In this video interview, Michel van Harten, MD, CEO, myTomorrows, discusses where the clinical research industry currently stands with AI adoption.

A pragmatic approach to streamlining technology and innovating processes will help advance clinical data management.

Companies share their experience in future-proofing clinical data technology.

In this video interview, Rob Jones, product manager, TMF practice area, Pharmalex, talks AI and how change is needed for the clinical trials industry to fully understand its potential with automation.

In this video interview, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, discusses how artificial intelligence can aid in bringing therapies to rare disease patients faster.

An increase in protocol complexity is paving the way for machine learning models to optimize trial design.

Andrew Mackinnon, Executive GM, Medable, discusses how AI-driven innovations are streamlining clinical trials through enabling scalable operations.

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, discusses industry’s next steps in being able to maximize the benefits of virtual models.